Saúde Pública/Medicina Humanitária

A study in @NatureMedicine shows that a smartwatch-based alerting system was able to detect pre-symptomatic and asymptomatic SARS-CoV-2 infection in a high percentage of cases. https://t.co/tquzpYa4pV pic.twitter.com/VIq3phKZ7J

— Nature Portfolio (@NaturePortfolio) November 30, 2021

Painel do FDA recomenda (por pouco) a autorização da primeira pílula antiviral para tratar COVID-19.

1 Dez, 2021 | 15:39h

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID – STAT

Ver também: An FDA panel supports Merck COVID drug in mixed vote – NPR

Conteúdos relacionados:

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

O fim da pandemia de COVID-19 está atrelado à confiança: a ciência sozinha não vai nos tirar disso.

1 Dez, 2021 | 15:34h

Ending the COVID-19 Pandemic Hinges on Trust – Think Global Health

Comentário no Twitter

Despite the availability of effective vaccines, deaths from #COVID in 2021 are two-thirds greater than the # of COVID-related deaths in 2020. @TomBollyky & @IHME_UW's Chris Troeger say trust—and the lack of it—has played a crucial role in the pandemic.https://t.co/8NiItD1wdc

— Think Global Health (@ThinkGlobalHlth) November 30, 2021

Diretrizes desenvolvidas sob pressão. O caso das diretrizes “rápidas” e de baixa qualidade para COVID-19 e soluções potenciais.

1 Dez, 2021 | 15:33h

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions – Journal of Clinical Epidemiology

Diretriz NICE | Tabaco: prevenção do consumo, promoção da interrupção do tabagismo e tratamento da dependência.

1 Dez, 2021 | 15:31h

Tobacco: preventing uptake, promoting quitting and treating dependence – National Institute for Health and Care Excellence

Relatório Clínico AAP | Promoção da participação de crianças e adolescentes com necessidades especiais em esportes, atividades físicas e de recreação.

1 Dez, 2021 | 15:29h

Promoting the Participation of Children and Adolescents With Disabilities in Sports, Recreation, and Physical Activity – Pediatrics

Comentário no Twitter

Children with disabilities benefit from physical activity of all kinds. Now is the time to focus on the inclusion of children based on their strengths and abilities, according to a clinical report published by AAP in Pediatrics this week.https://t.co/zlL9aOGwUU

— American Academy of Pediatrics (@AmerAcadPeds) November 30, 2021

Estimativas globais da supressão viral em 31 países mostram que muitos portadores do vírus HIV falharam em atingir uma supressão viral durável.

1 Dez, 2021 | 15:25h

Comunicado de imprensa: Too many people with HIV fail to achieve durable viral suppression – NIH News Releases

Estudo original: Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries – The Lancet HIV (link para o resumo – $ para o texto completo)

Oncologia integrativa | Direcionamento dos desafios globais de prevenção e tratamento de câncer.

1 Dez, 2021 | 15:22h

Integrative oncology: Addressing the global challenges of cancer prevention and treatment – Ca: A Cancer Journal for Clinicians

Comentário: Addressing the Global Challenges of Cancer Prevention and Treatment – The ASCO Post

Diretriz Científica AHA | Apoio à atividade física de pacientes e populações em eventos de vida e transições.

Orientações da OMS para o tráfego internacional em relação à variante Ômicron do SARS-CoV-2 (B.1.1.529).

Com dados de dispositivos móveis (wearable data), um sistema de alerta em tempo real pode ser útil na detecção precoce de Covid-19 e outros eventos estressores.